CTOs on the Move

Macrolide Pharmaceuticals

www.macrolidepharma.com

 
Macrolide Pharmaceuticals is a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity and will have broad applicability across multiple resistant infectious diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Macrolide Pharmaceuticals raised $20M on 04/02/2018

Similar Companies

Strategic BH Raleigh

Strategic Behavioral Health is a national mental health facility offering inpatient & outpatient treatment programs. We help families put their lives back together.

Pharmaceutics International

Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii`s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer contract analytical development and support formulation and manufacturing of oral solid dosage forms. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.

NLS Pharmaceutics

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Vindico Medical Education

Vindico Medical Education is a Thorofare, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.